YES, separating severe from critical for more deta
Post# of 148159
(Total Views: 528)
Posted On: 10/18/2020 1:31:27 PM
YES, separating severe from critical for more detailed Interim analysis, could be the best decision of the year related to covid-19, leading to Leronlimab's approval. However, that would make the number of patients smaller each of these 2 Interim analyses, and thus, might not calculate out to improved p value? Am I missing something here?
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼